CSS
APGE

Cubist Systematic Strategies’s Apogee Therapeutics APGE Stock Holding History

Cubist Systematic Strategies’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-91,213
Closed -$4.13M – 2828
2024
Q4 		$4.13M Buy
91,213
+7,236
+9% +$369K 0.03% 951
2024
Q3 		$4.93M Sell
83,977
-66,158
-44% -$3.17M 0.03% 838
2024
Q2 		$5.91M Buy
+150,135
New +$7.29M 0.04% 674

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return

Cubist Systematic Strategies's APGE Position: Q1 2025 in Review

Cubist Systematic Strategies sold out of Apogee Therapeutics (APGE) in Q1 2025, closing a stake of 91,213 shares — an estimated $4.13M sold.

Cubist Systematic Strategies first reported a position in APGE in Q2 2024 and held it in 3 quarters. The position peaked at $5.91M in Q2 2024. 168 funds tracked by Wall St. Rank hold APGE as of Q1 2025.

  • Cubist Systematic Strategies reported no remaining Apogee Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 91,213 Apogee Therapeutics shares in Q1 2025, an estimated $4.13M.
  • Cubist Systematic Strategies first reported a position in Apogee Therapeutics in Q2 2024 and held it in 3 quarters.
  • Cubist Systematic Strategies's Apogee Therapeutics position peaked at $5.91M in Q2 2024.
  • 168 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2025.

Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.